← Back to Calendar
Live Company Data
NCM
Updated
just now
· Data: FMP
Current Price
$14.95
+31.03%
+$3.54 today
Day: $14.61 – $15.47
Market Cap
N/A
Shares out: 102.21M
Float: 102.15M
52-Week Range
Current price is at 14% of 52-week range
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Thyroid eye disease (TED) — chronic, active
Key Notes
BLA accepted January 2026. PDUFA June 30, 2026. Positive Phase 3 THRIVE and THRIVE-2 trials — first Phase 3 trials to demonstrate diplopia response and resolution in chronic TED. Veligrotug is an anti-FcRn antibody administered every 3 weeks IV. Competitor to Tepezza (teprotumumab). Sub-$7B cap.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.